Context Therapeutics Inc. has submitted an IND application to the FDA to begin a first-in-human phase I study of CTIM-76 in patients with claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
Researchers presented the development of a translational pharmacokinetic (PK)/receptor occupancy (RO) model of the tetravalent bispecific antibody (bsAb) CTX-8371 (Compass Therapeutics LLC) with the aim of investigating the possible effects of tetravalency compared to bivalency on RO and target internalization.
Defence Therapeutics Inc. has announced the successful testing of a second-generation anticancer vaccine, ARM-002, using its lead anticancer molecule Accutox. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002 led to an 80% complete response when combined with an anti-PD-1 immune-checkpoint inhibitor.
Previous research has shown that adenosine impairs antitumor immunity, and high levels of adenosine and CD73 have been associated with poor prognosis in cancer.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Abl Bio Inc. have established a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
CSPC Pharmaceutical Group Ltd. has obtained clearance by China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6023 for advanced solid tumors.
Development and optimization of novel oral selective hematopoietic progenitor kinase 1 (HPK1) inhibitors for immuno-oncology (IO) treatment were reported by scientists from Astrazeneca plc in two presentations during the ACS meeting this week.
Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology.
Seven years since the first approval of two chimeric antigen receptor T-cell therapies for hematological cancers, U.S. and Singapore-based Immunoscape Pte Ltd. is looking to develop novel T-cell receptor (TCR) therapeutics for solid tumors.
RSS
